Reports > Technology And Media > Artificial Intelligence In Genomics Market Report
Artificial Intelligence In Genomics Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Artificial Intelligence in Genomics market from 2023 to 2033, exploring market size, growth rates, industry trends, regional insights, and key players influencing the sector.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $3.00 Billion |
| CAGR (2023-2033) | 12% |
| 2033 Market Size | $9.76 Billion |
| Top Companies | Illumina, Inc., Thermo Fisher Scientific Inc., Edgewise Therapeutics, Inc., Bristol Myers Squibb Company, Deep Genomics |
| Last Modified Date | 15 Nov 2024 |
Artificial Intelligence In Genomics Market Report (2023 - 2033)
Artificial Intelligence In Genomics Market Overview
What is the Market Size & CAGR of Artificial Intelligence In Genomics market in 2033?
Artificial Intelligence In Genomics Industry Analysis
Artificial Intelligence In Genomics Market Segmentation and Scope
Request a custom research report for industry.
Artificial Intelligence In Genomics Market Analysis Report by Region
Europe Artificial Intelligence In Genomics Market Report:
The European market for Artificial Intelligence in Genomics is anticipated to rise from $0.79 billion in 2023 to $2.56 billion by 2033. Key factors include supportive regulatory frameworks and increased emphasis on genomic research funded by both public and private sectors across European nations.Asia Pacific Artificial Intelligence In Genomics Market Report:
The Asia Pacific region is expected to experience substantial growth in the Artificial Intelligence in Genomics market, from $0.57 billion in 2023 to $1.86 billion by 2033. This growth is driven by increasing investments in healthcare technology and rising genomics research activities in countries like China and India, alongside a surge in personalized medicine adoption.North America Artificial Intelligence In Genomics Market Report:
North America continues to be a leading region in the Artificial Intelligence in Genomics market, forecasted to escalate from $1.17 billion in 2023 to $3.79 billion by 2033. The presence of significant biotech firms, robust healthcare infrastructure, and a well-established ecosystem for innovation underline this growth.South America Artificial Intelligence In Genomics Market Report:
The South America market for Artificial Intelligence in Genomics is projected to grow from $0.24 billion in 2023 to $0.78 billion by 2033. The region's expansion is supported by governmental initiatives to promote health technology and growing collaborations between local and international biotech firms.Middle East & Africa Artificial Intelligence In Genomics Market Report:
In the Middle East and Africa, the market is projected to grow from $0.24 billion in 2023 to $0.77 billion by 2033. This region is witnessing a gradual adoption of AI technologies as healthcare systems progress towards embracing genomics and precision medicine.Request a custom research report for industry.
Artificial Intelligence In Genomics Market Analysis By Technology
Global Artificial Intelligence in Genomics, By Technology Market Analysis (2023 - 2033)
The technology segment within the Artificial Intelligence in Genomics market showcases strong traction for machine learning and deep learning methods. In 2023, machine learning technology holds a significant market share, valued at $1.99 billion, expected to grow to $6.48 billion by 2033. Deep learning technologies also display promising growth, increasing from $0.60 billion in 2023 to approximately $1.97 billion by 2033.
Artificial Intelligence In Genomics Market Analysis By Application
Global Artificial Intelligence in Genomics, By Application Market Analysis (2023 - 2033)
The application sector is predominantly led by drug discovery and personalized medicine, holding a remarkable combined share. Drug discovery is anticipated to grow from $1.53 billion in 2023 to $4.99 billion by 2033, maintaining a share of 51.1%. Similarly, personalized medicine projects a growth trajectory from $0.73 billion to $2.36 billion during the same timeframe.
Artificial Intelligence In Genomics Market Analysis By End User
Global Artificial Intelligence in Genomics, By End User Market Analysis (2023 - 2033)
Pharmaceutical and biotechnology companies are the largest end-users in this market, with a size of $1.53 billion in 2023, projected to expand to $4.99 billion by 2033. Research institutions, making up 24.23% of the market share, are expected to see growth from $0.73 billion to $2.36 billion in the same period.
Artificial Intelligence In Genomics Market Analysis By Solution
Global Artificial Intelligence in Genomics, By Solution Market Analysis (2023 - 2033)
The solution landscape is diverse, focusing on cloud computing solutions and genetic testing software, alongside data analytics. The data analytics segment dominates with a forecast size of $1.99 billion in 2023, projected to scale to $6.48 billion by 2033, accounting for 66.41% of the market.
Artificial Intelligence In Genomics Market Analysis By Region
Global Artificial Intelligence in Genomics, By Region Market Analysis (2023 - 2033)
Regional analyses demonstrate that North America leads in overall market size, while Asia Pacific shows the fastest growth rate. Europe is characterized by investments in genomics infrastructure, and South America is gradually increasing traction through local collaborations in biotechnology.
Artificial Intelligence In Genomics Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Artificial Intelligence In Genomics Industry
Illumina, Inc.:
A leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function.Thermo Fisher Scientific Inc.:
Provides a broad range of analytical instruments, reagents, and consumables for scientific research and clinical diagnostics.Edgewise Therapeutics, Inc.:
A biotechnology company focused on discovering and developing novel therapies for patients with genetic diseases.Bristol Myers Squibb Company:
A global biopharmaceutical company engaged in discovering, developing, and delivering innovative medicines for patients.Deep Genomics:
An AI-based genomics company building the future of medicine by discovering and developing therapies for genetic disorders.We're grateful to work with incredible clients.
